Annual EBITDA
-$32.49 M
-$7.69 M-31.00%
30 September 2022
Summary:
NeuBase Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$32.49 million, with the most recent change of -$7.69 million (-31.00%) on 30 September 2022. During the last 3 years, it has fallen by -$7.69 million (-31.00%).NBSE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$1.57 M
+$1.57 M+50.01%
30 September 2023
Summary:
NeuBase Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$1.57 million, with the most recent change of +$1.57 million (+50.01%) on 30 September 2023.NBSE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$12.55 M
+$5.72 M+31.32%
30 September 2023
Summary:
NeuBase Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$12.55 million, with the most recent change of +$5.72 million (+31.32%) on 30 September 2023.NBSE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBSE EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -31.0% | +79.2% | +55.7% |
| 5 y5 years | -25.6% | +63.9% | +56.9% |
NBSE EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -354.4% | -112.4% | -155.4% |
NeuBase Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$1.57 M(-50.0%) | -$12.55 M(-31.3%) |
| June 2023 | - | -$3.14 M(-17.1%) | -$18.27 M(-21.5%) |
| Mar 2023 | - | -$3.79 M(-6.4%) | -$23.29 M(-19.7%) |
| Dec 2022 | - | -$4.05 M(-44.5%) | -$29.01 M(-10.7%) |
| Sept 2022 | -$32.49 M(+31.0%) | -$7.29 M(-10.6%) | -$32.49 M(+1.3%) |
| June 2022 | - | -$8.16 M(-14.1%) | -$32.09 M(-1.0%) |
| Mar 2022 | - | -$9.50 M(+26.2%) | -$32.42 M(+14.4%) |
| Dec 2021 | - | -$7.53 M(+9.3%) | -$28.34 M(+14.3%) |
| Sept 2021 | -$24.80 M(+45.1%) | -$6.89 M(-18.8%) | -$24.80 M(+9.9%) |
| June 2021 | - | -$8.49 M(+56.3%) | -$22.56 M(+26.5%) |
| Mar 2021 | - | -$5.43 M(+36.2%) | -$17.83 M(+6.6%) |
| Dec 2020 | - | -$3.99 M(-14.2%) | -$16.73 M(-2.1%) |
| Sept 2020 | -$17.10 M(-33.9%) | -$4.65 M(+23.3%) | -$17.10 M(-51.5%) |
| June 2020 | - | -$3.77 M(-13.0%) | -$35.26 M(+8.6%) |
| Mar 2020 | - | -$4.33 M(-0.6%) | -$32.46 M(+11.5%) |
| Dec 2019 | - | -$4.35 M(-80.9%) | -$29.12 M(+14.2%) |
| Sept 2019 | -$25.87 M(+225.3%) | -$22.81 M(+2248.1%) | -$25.51 M(+634.1%) |
| June 2019 | - | -$971.30 K(-1.8%) | -$3.47 M(+2.5%) |
| Mar 2019 | - | -$988.90 K(+33.8%) | -$3.39 M(-4.9%) |
| Dec 2018 | - | -$739.00 K(-4.7%) | -$3.57 M(-47.0%) |
| Sept 2018 | -$7.95 M(-64.9%) | -$775.40 K(-12.6%) | -$6.72 M(-38.4%) |
| June 2018 | - | -$887.30 K(-23.8%) | -$10.92 M(-20.1%) |
| Mar 2018 | - | -$1.16 M(-70.1%) | -$13.67 M(-31.3%) |
| Dec 2017 | - | -$3.90 M(-21.6%) | -$19.91 M(-12.3%) |
| Sept 2017 | -$22.69 M(-5.9%) | -$4.97 M(+36.7%) | -$22.69 M(-6.3%) |
| June 2017 | - | -$3.64 M(-50.8%) | -$24.22 M(-13.1%) |
| Mar 2017 | - | -$7.40 M(+10.8%) | -$27.89 M(+1.4%) |
| Dec 2016 | - | -$6.68 M(+2.6%) | -$27.50 M(+14.0%) |
| Sept 2016 | -$24.12 M(+48.1%) | -$6.51 M(-10.9%) | -$24.12 M(+16.1%) |
| June 2016 | - | -$7.30 M(+4.2%) | -$20.77 M(+25.7%) |
| Mar 2016 | - | -$7.01 M(+112.8%) | -$16.52 M(+3.1%) |
| Dec 2015 | - | -$3.29 M(+4.1%) | -$16.02 M(-2.0%) |
| Sept 2015 | -$16.29 M(+88.1%) | -$3.16 M(+3.7%) | -$16.34 M(+2.4%) |
| June 2015 | - | -$3.05 M(-53.1%) | -$15.96 M(+7.6%) |
| Mar 2015 | - | -$6.51 M(+79.9%) | -$14.84 M(+44.4%) |
| Dec 2014 | - | -$3.62 M(+30.1%) | -$10.28 M(+18.7%) |
| Sept 2014 | -$8.66 M(+55.8%) | -$2.78 M(+44.0%) | -$8.66 M(+13.1%) |
| June 2014 | - | -$1.93 M(-0.8%) | -$7.65 M(+8.8%) |
| Mar 2014 | - | -$1.95 M(-2.6%) | -$7.04 M(+31.3%) |
| Dec 2013 | - | -$2.00 M(+12.5%) | -$5.36 M(-3.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2013 | -$5.56 M(+307.0%) | -$1.78 M(+35.3%) | -$5.56 M(+50.6%) |
| June 2013 | - | -$1.31 M(+385.2%) | -$3.69 M(+31.1%) |
| Mar 2013 | - | -$270.70 K(-87.7%) | -$2.81 M(-28.5%) |
| Dec 2012 | - | -$2.20 M(-2531.7%) | -$3.93 M(+188.1%) |
| Sept 2012 | -$1.37 M(-72.8%) | $90.30 K(-120.6%) | -$1.37 M(-51.1%) |
| June 2012 | - | -$438.10 K(-68.5%) | -$2.79 M(-49.0%) |
| Mar 2012 | - | -$1.39 M(-472.9%) | -$5.47 M(+29.7%) |
| Dec 2011 | - | $372.90 K(-127.9%) | -$4.22 M(-15.9%) |
| Sept 2011 | -$5.02 M(-1035.2%) | -$1.34 M(-57.1%) | -$5.02 M(+86.8%) |
| June 2011 | - | -$3.12 M(+2193.4%) | -$2.68 M(-1140.5%) |
| Mar 2011 | - | -$135.90 K(-68.1%) | $258.00 K(+6.2%) |
| Dec 2010 | - | -$425.70 K(-142.8%) | $242.90 K(-52.9%) |
| Sept 2010 | $536.30 K(-163.9%) | $993.70 K(-670.8%) | $515.80 K(-186.8%) |
| June 2010 | - | -$174.10 K(+15.3%) | -$594.20 K(-6.5%) |
| Mar 2010 | - | -$151.00 K(-1.2%) | -$635.40 K(-31.3%) |
| Dec 2009 | - | -$152.80 K(+31.4%) | -$924.80 K(+10.3%) |
| Sept 2009 | -$838.70 K(+28.3%) | -$116.30 K(-46.0%) | -$838.40 K(-17.9%) |
| June 2009 | - | -$215.30 K(-51.1%) | -$1.02 M(+24.5%) |
| Mar 2009 | - | -$440.40 K(+563.3%) | -$820.40 K(+72.4%) |
| Dec 2008 | - | -$66.40 K(-77.8%) | -$476.00 K(-27.1%) |
| Sept 2008 | -$653.60 K(<-9900.0%) | -$299.60 K(+2040.0%) | -$652.60 K(+84.9%) |
| June 2008 | - | -$14.00 K(-85.4%) | -$353.00 K(+4.1%) |
| Mar 2008 | - | -$96.00 K(-60.5%) | -$339.00 K(-81.9%) |
| Dec 2007 | - | -$243.00 K(<-9900.0%) | -$1.87 M(+15.0%) |
| Sept 2007 | $0.00(0.0%) | $0.00(0.0%) | -$1.63 M(0.0%) |
| June 2007 | - | $0.00(-100.0%) | -$1.63 M(+1.7%) |
| Mar 2007 | - | -$1.63 M(<-9900.0%) | -$1.60 M(-147.0%) |
| Dec 2006 | $0.00(-100.0%) | $0.00(0.0%) | $3.40 M(-78.9%) |
| Sept 2006 | - | $0.00(-100.0%) | $16.11 M(-17.2%) |
| June 2006 | - | $26.70 K(-99.2%) | $19.46 M(-14.2%) |
| Mar 2006 | - | $3.38 M(-73.4%) | $22.67 M(+1.8%) |
| Dec 2005 | $12.77 M(+35.7%) | $12.71 M(+279.0%) | $22.26 M(+83.5%) |
| Sept 2005 | - | $3.35 M(+3.6%) | $12.13 M(+9.4%) |
| June 2005 | - | $3.24 M(+9.1%) | $11.09 M(+9.0%) |
| Mar 2005 | - | $2.97 M(+15.0%) | $10.18 M(+8.4%) |
| Dec 2004 | $9.41 M(+45.1%) | $2.58 M(+11.6%) | $9.39 M(+37.9%) |
| Sept 2004 | - | $2.31 M(-0.4%) | $6.81 M(+51.5%) |
| June 2004 | - | $2.32 M(+6.9%) | $4.49 M(+106.9%) |
| Mar 2004 | - | $2.17 M | $2.17 M |
| Dec 2003 | $6.49 M | - | - |
FAQ
- What is NeuBase Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for NeuBase Therapeutics?
- What is NeuBase Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for NeuBase Therapeutics?
- What is NeuBase Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for NeuBase Therapeutics?
What is NeuBase Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of NBSE is -$32.49 M
What is the all time high annual EBITDA for NeuBase Therapeutics?
NeuBase Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is $12.77 M
What is NeuBase Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of NBSE is -$1.57 M
What is the all time high quarterly EBITDA for NeuBase Therapeutics?
NeuBase Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $12.71 M
What is NeuBase Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of NBSE is -$12.55 M
What is the all time high TTM EBITDA for NeuBase Therapeutics?
NeuBase Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $22.67 M